Sherry Rohekar

Jun 24, 2024 | jrheum.org | Sherry Rohekar |Reza Mirza |Sibel Zehra Aydin |Louis Bessette

Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis Sherry Rohekar, Jordi Pardo Pardo, Reza Mirza, Sibel Zehra Aydin, Louis Bessette, Nicolas Richard, Dianne Mosher, Tristan Boyd, Jon Chan, Lihi Eder, Laura Passalent, Elie Karam, Bindu Nair, Glen S.

May 6, 2024 | acrjournals.onlinelibrary.wiley.com | Sherry Rohekar |Aisha Vadhariya |Sarah Ross

INTRODUCTION Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease.

May 1, 2024 | jrheum.org | Dafna D Gladman |Vinod Chandran |Cheryl Rosen |Sherry Rohekar

Key Indexing Terms: advanced therapy antirheumatic agents burden of disease psoriatic arthritis residual disease activity Psoriatic arthritis (PsA) is a type of arthritis associated with cutaneous psoriasis, and is a progressive, systemic inflammatory disease that can result in joint damage, functional impairment, extramusculoskeletal manifestations (EMMs; such as uveitis and inflammatory bowel disease), reduced quality of life, and early mortality.1-5 However, patient outcomes have improved...

Feb 9, 2024 | jrheum.org | Dafna D Gladman |Vinod Chandran |Cheryl Rosen |Sherry Rohekar

Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA) Dafna D. Gladman, Vinod Chandran, Cheryl F. Rosen, Sherry Rohekar, Tristan Boyd, Lihi Eder, Proton Rahman, Jan Dutz, Jonathan Chan, Richard P.